Guardant Health Inc (NASDAQ:GH) Shares Bought by Candriam Luxembourg S.C.A.

Share on StockTwits

Candriam Luxembourg S.C.A. raised its position in Guardant Health Inc (NASDAQ:GH) by 466.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 57,752 shares of the company’s stock after acquiring an additional 47,552 shares during the quarter. Candriam Luxembourg S.C.A. owned 0.06% of Guardant Health worth $4,514,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of GH. Point72 Asset Management L.P. grew its position in shares of Guardant Health by 13,607.6% during the third quarter. Point72 Asset Management L.P. now owns 765,023 shares of the company’s stock worth $48,831,000 after buying an additional 759,442 shares in the last quarter. State Street Corp boosted its holdings in Guardant Health by 13.7% in the third quarter. State Street Corp now owns 502,485 shares of the company’s stock worth $32,074,000 after purchasing an additional 60,666 shares during the period. FMR LLC boosted its holdings in Guardant Health by 28.3% in the first quarter. FMR LLC now owns 464,612 shares of the company’s stock worth $35,636,000 after purchasing an additional 102,483 shares during the period. Massachusetts Financial Services Co. MA boosted its holdings in Guardant Health by 15.9% in the third quarter. Massachusetts Financial Services Co. MA now owns 433,560 shares of the company’s stock worth $27,673,000 after purchasing an additional 59,426 shares during the period. Finally, Sumitomo Mitsui Trust Holdings Inc. boosted its holdings in Guardant Health by 43.0% in the fourth quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 376,307 shares of the company’s stock worth $29,405,000 after purchasing an additional 113,239 shares during the period. 78.53% of the stock is owned by institutional investors.

GH stock opened at $84.30 on Friday. Guardant Health Inc has a 1 year low of $49.25 and a 1 year high of $112.21. The stock’s fifty day moving average is $79.79 and its two-hundred day moving average is $78.90.

GH has been the subject of a number of research reports. Citigroup initiated coverage on shares of Guardant Health in a report on Monday, January 6th. They issued a “buy” rating and a $100.00 price objective for the company. Zacks Investment Research raised shares of Guardant Health from a “hold” rating to a “strong-buy” rating and set a $90.00 price objective for the company in a report on Wednesday, January 29th. William Blair reaffirmed an “outperform” rating on shares of Guardant Health in a report on Friday, November 8th. Canaccord Genuity reaffirmed a “buy” rating and issued a $125.00 price objective on shares of Guardant Health in a report on Friday, November 8th. Finally, ValuEngine downgraded shares of Guardant Health from a “buy” rating to a “hold” rating in a report on Tuesday, December 3rd. One research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $107.33.

In other Guardant Health news, Director Ian T. Clark sold 538 shares of the firm’s stock in a transaction on Monday, January 27th. The stock was sold at an average price of $77.31, for a total value of $41,592.78. Following the sale, the director now directly owns 1,840 shares in the company, valued at $142,250.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Stanley J. Meresman sold 5,000 shares of the firm’s stock in a transaction on Wednesday, January 15th. The shares were sold at an average price of $79.55, for a total value of $397,750.00. Following the completion of the sale, the director now owns 6,302 shares in the company, valued at $501,324.10. The disclosure for this sale can be found here. Insiders sold 175,061 shares of company stock worth $13,929,591 over the last quarter. 13.00% of the stock is currently owned by company insiders.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers liquid biopsy tests for advanced stage cancer, such as Guardant360, a molecular diagnostic test that measures various cancer-related genes; and GuardantOMNI, a broader gene panel, including genes associated with homologous recombination repair deficiency and biomarkers for immuno-oncology applications.

Read More: Why Invest in Dividend Achievers?

Institutional Ownership by Quarter for Guardant Health (NASDAQ:GH)

Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Barclays PLC Purchases 623,296 Shares of AmeriCold Realty Trust
Barclays PLC Purchases 623,296 Shares of AmeriCold Realty Trust
Equity Lifestyle Properties, Inc.  Shares Acquired by Barclays PLC
Equity Lifestyle Properties, Inc. Shares Acquired by Barclays PLC
Barclays PLC Has $25.37 Million Holdings in Zebra Technologies
Barclays PLC Has $25.37 Million Holdings in Zebra Technologies
Barclays PLC Has $27.64 Million Stake in UDR, Inc.
Barclays PLC Has $27.64 Million Stake in UDR, Inc.
Barclays PLC Reduces Stake in SPDR S&P Aerospace & Defense ETF
Barclays PLC Reduces Stake in SPDR S&P Aerospace & Defense ETF
BCS Wealth Management Takes $10.48 Million Position in Invesco BulletShares 2020 Corporate Bond ETF
BCS Wealth Management Takes $10.48 Million Position in Invesco BulletShares 2020 Corporate Bond ETF


© 2006-2020 Ticker Report